Applied Clinical Trials-04-01-2015

Media rebuke of Europe’s Innovative Medicines Initiative thrusts debate into the public arena.

Study shows that industry contributions to R&D go well beyond the applied area of clinical testing.

Successful conduct of hematological malignancy trials requires addressing several unique complexities.

How the practical application of these methods can help overcome the complex demands of cancer trials.

Evaluating the use of new tumor measurement tools for studies of molecular-targeted cancer therapies.

The need for robust and standardized psychiatric outcomes measures in oncology trials has grown immensely

Building a structure for managing study operations through linking trial- and site-level forecasting.

Faster go/no-go decisions is the primary driver of adaptive-design adoption by sponsors.

The productivity of the U.S. biomedical research enterprise is undergoing a broad re-examination.

Initiative designed to boost understanding of medical device development in Europe.

Patient focused drug development is playing a larger role in study design and outcome measurement.

New ASCO study evaluating the cancer care system reveals mixed findings.

Outlining the requirements and benefits of FDA's four expedited drug approval pathways.

Following four key study-design steps is crucial to the delivery of a successful cross-border cancer study

Trial Design: Breaking Blood Cancer Barriers Adaptive Solutions in Oncology Clinical Technology: Tumor Imaging Ascension Sites: Enrollment Forecast Data Also in this issue: Innovation Initiative Debate in Europe R&D Investment: Public vs. Private The Psychology of Cancer